Article thumbnail

Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort

By Matthias Stoll, Christian Kollan, Frank Bergmann, Johannes Bogner, Gerd Faetkenheuer, Carlos Fritzsche, Kirsten Hoeper, Heinz-August Horst, Jan van Lunzen, Andreas Plettenberg, Stefan Reuter, Jürgen Rockstroh, Hans-Jürgen Stellbrink, Osamah Hamouda and Barbara Bartmeyer
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.
  2. (2010). Cohort profile: the German ClinSurv HIV project–a multicentre open clinical cohort study supplementing national HIV surveillance.
  3. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.
  4. (2002). Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART.
  5. (2009). Effects of the German reference drug program on ex factory prices of prescription drugs: a panel data approach.
  6. (2010). Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
  7. (2010). Estimation of patients with antiretroviral therapy potentially used for HIV prevention (postexposure prophylaxis, mother to child transmission prophylaxis) in
  8. (2009). Generic script share and the price of brand-name drugs: the role of consumer choice. International journal of health care finance and economics 9:
  9. (2011). German Federal Ministry of Justice: German Social Insurance Code from 1989, last revision from 28 th
  10. (2005). German health care system in transition. The difficult way to balance cost containment and solidarity.
  11. (2010). German-Austrian Treatment Guidelines for antiretroviral therapy (Deutsch-O
  12. (2009). Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
  13. (2009). Government Regulation of Pricing and Reimbursement of Prescription Medicines: Results of a Recent Multi-Country Review. Food Drug
  14. (2009). Guidelines Clinical Management and Treatment of HIV-infected Adults
  15. (2011). Guidelines for the Use of Antiretroviral Agents
  16. (2009). Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.
  17. (2006). In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.
  18. (2010). Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.
  19. (2010). Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane database of systematic reviews (Online).
  20. (2007). Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany.
  21. (2005). Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence.
  22. (2007). Short communication A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
  23. (2004). Side effects of generic competition?
  24. (2009). Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.
  25. (2006). The direct costs of HIV/AIDS care. The Lancet infectious diseases 6:
  26. (2010). The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study.
  27. (2006). The survival benefits of AIDS treatment in the United States. The Journal of infectious diseases 194:
  28. (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study.